Wu G, Tang W, Lv D, Wu L, Zhou H, Yang X, Zheng Y, Zhai Y, Shentu J. Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous
Morinidazole in Healthy Chinese Subjects.
Antimicrob Agents Chemother 2020;
64:e02067-19. [PMID:
32152080 DOI:
10.1128/AAC.02067-19]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Accepted: 02/11/2020] [Indexed: 11/20/2022] Open
Abstract
The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC0-∞) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF. No unexpected safety or tolerability issues were observed.
Collapse